Dey T, Yadav BS. Anaplastic thyroid cancer: Unveiling advances in diagnosis and management. World J Clin Oncol 2024; 15(7): 786-789 [PMID: 39071466 DOI: 10.5306/wjco.v15.i7.786]
Corresponding Author of This Article
Budhi Singh Yadav, MD, Professor, Department of Radiotherapy & Oncology, Post-Graduate Institute of Medical Education & Research, Sector 12, Chandigarh 160012, India. drbudhi@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jul 24, 2024; 15(7): 786-789 Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.786
Anaplastic thyroid cancer: Unveiling advances in diagnosis and management
Treshita Dey, Budhi Singh Yadav
Treshita Dey, Budhi Singh Yadav, Department of Radiotherapy & Oncology, Post- Graduate Institute of Medical Education & Research, Chandigarh 160012, India
Author contributions: Yadav BS and Dey T contributed to conceptualization, literature review, manuscript writing, editing, and final approval.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Budhi Singh Yadav, MD, Professor, Department of Radiotherapy & Oncology, Post-Graduate Institute of Medical Education & Research, Sector 12, Chandigarh 160012, India. drbudhi@gmail.com
Received: December 29, 2023 Revised: May 22, 2024 Accepted: June 11, 2024 Published online: July 24, 2024 Processing time: 199 Days and 15.9 Hours
Abstract
The review article by Pavlidis et al published in World J Clin Oncol provides a meticulous analysis of the intricacies surrounding anaplastic carcinoma of the thyroid. Thyroid carcinoma encompasses a spectrum of diseases, each characterized by distinct behaviors and outcomes. Diagnostic approaches encompass a diverse array of tools. Surgery remains the pivotal treatment for anaplastic thyroid carcinoma. Radiotherapy and chemotherapy offer the best overall survival in aggressive disease. Combinations of immunotherapy with targeted therapies, such as dabrafenib-trametinib, demonstrate potential for enhanced effectiveness and improved survival outcomes. Multifaceted approach fuelled by precision medicine and interdisciplinary collaboration is imperative in charting a course toward improved outcomes in this formidable malignancy.
Core Tip: Anaplastic thyroid cancer is an aggressive disease. Surgery is the main treatment. Combination of radiotherapy and chemotherapy help to further improve the outcome of patients with this malignancy. Immunotherapy, targeted therapies, and molecular insights herald a new dawn for a patient cohort hitherto consigned to bleak prognoses.
